publication date: Aug. 4, 2016

NCI CTEP-Approved Trials for the Month of July

 

The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.

 

Phase I

9924: A Phase I Trial of the Combination of Lenalidomide and Blinatumomab in Patients with Relapsed or Refractory Non-Hodgkins Lymphoma (NHL). City of Hope Comprehensive Cancer Center LAO; Tuscano, Joseph M. (916) 734-3771

 

Phase II

9925: Phase II Trial of Nivolumab for HTLV-Associated Adult T Cell Leukemia/Lymphoma. Duke University – Duke Cancer Institute LAO; Ratner, Lee. (314) 362-8836

AMC-098: A Pilot Study of Nelfinavir for the Treatment of Kaposi Sarcoma. AIDS Malignancy Consortium; Gantt, Soren Matthew. (206) 987-1160

S1513: Randomized Phase II Study of 2nd Line FOLFIRI Versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer. SWOG; Chiorean, Elena Gabriela. (206) 288-6248

 

Other Phases

AALL16B6-Q: Identifying the T681I Gatekeeper Mutation in EBF1-PDGFRB Ph-like ALL Using Droplet Digital PCR (ddPCR). Children’s Oncology Group; Tran, Thai Hoa. (215) 590-6359

AMC-A03: Validation of a Health-Related Symptom Index for Persons Diagnosed with and Either Treated or Monitored for Anal High-Grade Squamous Intraepithelial Lesions (HSIL). AIDS Malignancy Consortium; Burkhalter, Jack Eryn. (646) 888-0040

ANBL14B8-Q: Prognostic Significance of the Neuroblastoma 14-Gene Signature for Patients with High-Risk Stage 3 Tumors … Continue reading CCL July – NCI CTEP-Approved Trials for the Month of July

To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2017 The Cancer Letter Inc.